We recently published a list of 8 Best Gene-Editing Stocks to Buy. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best gene-editing stocks to buy.

Meanwhile, the first major obesity-related phase 3 trial for orforglipron is set to complete in July. If the data from the diabetes trial looks good, investors may expect that the weight loss data will also be strong as effective diabetes treatments usually help patients lose weight.

Tobacco giant Altria (NYSE: MO) provides a tremendously high dividend yield of 7%, which is well above the S&P 500 index average of 1.3%. Meanwhile, pharma company Eli Lilly (NYSE: LLY) offers a much lower yield of less than 1%,